

Impoyz™ (clobetasol propionate) – New drug approval

- On November 28, 2017, the FDA approved Promius Pharma's [Impoyz \(clobetasol propionate\)](#) 0.025% cream, for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older.
- Clobetasol propionate is also available generically as a 0.05% [cream](#), 0.05% [emollient cream](#), 0.05% [foam](#), 0.05% [gel](#), 0.05% [liquid spray](#), 0.05% [lotion](#), 0.05% [ointment](#), 0.05% [shampoo](#), and 0.05% [solution](#).
 - Refer to individual drug labels for indication information.
- The approval of Impoyz was based on two vehicle-controlled studies evaluating 532 patients ≥ 18 years with moderate to severe plaque psoriasis. The primary endpoint was the proportion of subjects who achieved treatment success at day 15.
 - In study 1, 30.2% of Impoyz-treated patients achieved the primary endpoint vs. 9.0% of vehicle-treated patients.
 - In study 2, 30.1% of Impoyz-treated patients achieved the primary endpoint vs. 9.7% of vehicle-treated patients.
- Warnings and precautions of Impoyz include effects on the endocrine system, local adverse reactions, concomitant skin infections, and allergic contact dermatitis.
- The most common adverse reaction (≥ 1%) with Impoyz use was application site discoloration.
- Impoyz should be applied as a thin layer to the affected skin areas twice daily and rubbed in gently and completely.
 - Impoyz may be used for up to two consecutive weeks.
 - The total dosage should not exceed 50 grams/week.
 - Do not use on the face, scalp, axilla, groin, or other intertriginous areas.
- Promius Pharma's launch plans for Impoyz are pending. Impoyz will be available as a 0.025% cream in 60 g and 112 g tubes.